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Abstract. – OBJECTIVE: Hepatitis C virus 
(HCV) infection is a global epidemic, still highly 
prevalent in Europe. Given efficacy and safety 
of HCV therapy by Direct Antiviral Agents (DAA), 
World Health Organization called for actions to 
eliminate HCV infection. A limit is represented 
by access to care, mostly due to the high costs 
of medicines. In Italy, in 2015, the access to DAA 
therapy was reimbursed for patients with ad-
vanced disease, whereas in 2017 universal ac-
cess was granted. The aim of this study was to 
analyse changes in patient recruitment trends 
treated with DAA with or without limitations to 
access to therapy.
PATIENTS AND METHODS: 165,105 patients 
treated with DAA in Italy from 2015 to December 
2018 were analysed. Daily patient treatment rate 
was obtained by segmented regression of inter-
rupted time series analysis. 
RESULTS: 74,199 patients with advanced dis-
ease (62% with cirrhosis) had access to the ther-
apy during the time period from 2015 to 2017. 
Following the extension of reimbursement cri-
teria, 90,906 additional patients were treated 
(43.2% with F0-F1 and 22.9% with F2), with an 
absolute reduction of 59.9% of patients with ad-
vanced disease (cirrhosis decreased to 18.5%). 
Segmented regression of interrupted time series 
analysis of daily patient treatment rate showed a 
progressive reduction of patients with advanced 
disease, offset by those with initial disease. No-
tably, elimination of restrictions to therapy did 
not change the overall treatment rate. 
CONCLUSIONS: This study showed that a 
no-limit reimbursement policy for DAAs pre-
scriptions to HCV infected individuals in Italy 
widened the types of treated patients, but the 
process towards elimination of HCV infection 
was not significantly changed.
Key Words:
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HCV = Hepatitis C Virus; DAA = Direct Antiviral 
Agents; WHO = World Health Organization; AIFA = 
Agenzia Italiana del Farmaco (Italian Medicine Agency).
Introduction
Chronic viral hepatitis today still represents a 
major global clinical challenge, causing over 1.3 
million deaths per year1. It is estimated that 360 
million people are infected by hepatitis viruses, 
71 million of which by chronic Hepatitis C Virus 
(HCV) hepatitis1. Chronic hepatitis C retains a 
relevant mortality, with 400,000 deaths on an 
annual basis, with liver decompensation or hepa-
tocellular carcinoma being responsible for 96% of 
all liver-related mortality1. 
HCV infection is a global epidemic, with inci-
dence and prevalence differing by countries and 
regions. The global prevalence of HCV infec-
tion is estimated to be 1%. Generally speaking, 
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however, HCV infection is mostly associated to 
unsafe health-care-related injections and, there-
fore, with lower social/economic conditions, 
HCV infection is still highly prevalent in Euro-
pean countries, ranging from 1.2 to 1.5%1. The 
European region is second only to the Eastern 
Mediterranean Region as far as HCV prevalence 
is concerned1. 
The natural history of chronic hepatitis C has 
changed after the introduction of second-gen-
eration Direct Antiviral Agents (DAAs), which 
resulted effective in safely eliminating HCV in-
fection in 95% of treated patients2,3. This has 
prompted major international institutions to elab-
orate strategies to eliminate HCV from com-
munities. One of the most important of such 
strategies has been proposed by the World Health 
Organization (WHO), in which treatment is one 
of the three pillars1. 
Italy has a high HCV prevalence, estimated to 
be one of the highest in Europe. Studies conduct-
ed in local cohorts showed that HCV prevalence 
might range from 8% among those born in the 
thirties of the twentieth century to less than 1% 
in those born during the second half4. However, 
at a national level, so far there has been no im-
plementation of an Italian epidemiological reg-
istry which could have facilitated a more precise 
definition of the number and disease severity of 
patients affected by HCV.
Difficulty in accessing care is a well-known 
obstacle for the implementation of an effective 
global plan for disease eradication. This is even 
more relevant in the case of HCV, given the high 
costs of drugs especially at time of their first ne-
gotiation and even more relevant in countries like 
Italy, offering a universal public healthcare sys-
tem. During 2015, in a condition of a presumed 
high number of patients to be treated and finan-
cial constraints given by the high cost of therapy, 
full drug reimbursement was granted only to 
HCV patients at higher risks of disease progres-
sion or complications. Later, in 2017, thanks to 
the decrease in pricing due to competition from 
new DAAs, the criteria for reimbursement were 
expanded in the market, allowing access to ther-
apy for all patients infected by HCV.
This study aims at analysing changes in patient 
recruitment trends treated with DAA with or 
without limitations to access to therapy. We spe-
cifically asked the following questions: 1) did the 
expansion of DAA reimbursement criteria change 
the clinical background of the patient population 
who would access therapy?; (2) did the expansion 
of DAA reimbursement criteria change the rate of 
patients treated per week?; (3) did the expansion 
of DAA reimbursement criteria favour the treat-
ment of patients with more advanced diseases?
 
Patients and Methods
The first product for the treatment of chronic C 
hepatitis belonging to the pharmacological class 
of DAAs was reimbursed by the Italian Nation-
al Health Service (NHS) in December of 2014. 
During 2015, more products were gradually con-
sidered for reimbursement. Initially, considering 
the prevalence of HCV infection in the country, 
the reimbursement of all DAAs in Italy was limit-
ed on the basis of detailed criteria (Table I) which 
identified the specific clinical conditions allowing 
patient access to new innovative treatments. To 
begin with, reimbursement criteria focused on 
less frequent HCV patients, with more severe 
clinical conditions. In particular, patient access 
to DAAs treatment was granted to cirrhotic pa-
tients, or having a hepatocellular carcinoma (i.e., 
first reimbursement criterion); or HCV patients 
managed by transplant centres (i.e., second, fifth 
and sixth reimbursement criteria); or patients 
having severe HCV-related extra-hepatic mani-
festations (i.e., third reimbursement criterion); or 
patients having severe to middle hepatic fibrosis 
(i.e., fourth and seventh reimbursement criteria, 
respectively). 
From March 31st, 2017 (Table I), the Italian 
Medicines Agency AIFA expanded the reim-
bursement criteria of DAAs allowing treatment 
for less severely affected HCV patients. The new 
criterion allowed DAAs treatment of HCV pa-
tients having slight or none hepatic fibrosis (i.e., 
eighth reimbursement criterion), health workers 
(i.e., nineth reimbursement criterion), patients 
under haemodialysis (i.e., tenth reimbursement 
criterion) and patients on waiting lists for any 
kind of transplant (i.e., eleventh reimbursement 
criterion).
Considering the high prevalence of infected in-
dividuals in Italy with estimates ranging between 
400,000 to 600,000 HCV patients, the extension 
of reimbursement to DAAs was expected to sig-
nificantly increase patient access, speeding up the 
process towards the eradication of HCV infec-
tion. Therefore, the null hypothesis of this study 
states that h0 = daily patient rate starting DAA 
treatment remains unchanged after the addition 
of four new reimbursement criteria. 
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*HBV coinfection, HIV coinfection, chronic non-viral liver disease, diabetes mellitus in pharmacological treatment, obesity (body mass index ≥ 30 kg/m2), hemoglobinopathies 
and congenital coagulopathies. 
Table I. Reimbursement criteria for starting DAAs in Italy. Number and frequency of patients starting DAAs for each reimbursement criteria before and after introduction of new criteria.
   Before new After new 
   reimbursement criteria reimbursement criteria 
   (until to April 2017) (until to December 2018) 
 Criterion      % 
 number Criterion definition No. % No. % difference
 1 Patients having cirrhosis in Child A or B class and/or  46,338 62.5% 16,837 18.5% -44.0%
 having HCC with complete response to surgical resection or 
 loco-regional therapies not eligible for hepatic transplantation 
 in which hepatic disease is determinant for prognosis 
 2 Recurrent HCV-RNA hepatitis of the transplanted liver in a  1,958 2.6% 2,277 2.5% -0.1%
 clinically stable patient and with optimal levels of immunosuppression 
 3 Chronic hepatitis with severe HCV-related extra-hepatic  3,626 4.9% 4,635 5.1% 0.2%
 manifestations (cryoglobulinemic syndrome with organ damage,  
 B-cell lymphoproliferative syndromes, renal failure). 
 4 Chronic hepatitis with fibrosis METAVIR F3 (or corresponding Ishak). 20,974 28.3% 11,742 12.9% -15.4%
 5 Patient on the waiting-list for liver transplantation having MELD 300 0.4% 35 0.0% -0.4%
 cirrhosis < 25 and/or having HCC within the Milan criteria, with 
 possibility of a waiting in the list for at least 2 months. 
 6 Chronic hepatitis after solid organ transplantation (non-liver) or 375 0.5% 233 0.3% -0.2%
 bone marrow in clinically stable patient and with optimal levels  
 of immunosuppression. 
 7 Chronic hepatitis with METAVIR F2 fibrosis (or corresponding 628 0.8% 20,825 22.9% 22.1%
 Ishak) and/or co-morbidity at risk of progression of hepatic injury*     
 8 Chronic hepatitis with fibrosis METAVIR F0-F1 (or corresponding    39,240 43.2% 43.2%
 Ishak) and/or co-morbidity at risk of progression of hepatic injury*     
 New criterion legally introduced from 31st March 2017     
 9 Infected health workers.   262 0.3% 0.3%
 New criterion legally introduced from 31st March 2017     
10 Chronic hepatitis or liver cirrhosis in patients having chronic    384 0.4% 0.4%
 renal failure under haemodialysis.     
 New criterion legally introduced from 31st March 2017     
11 Chronic hepatitis in the patient on the waiting-list for solid organ    14 0.0% 0.0%
 transplantation (non-liver) or marrow transplantation.     
 New criterion legally introduced from 31st March 2017     
Total   74,199 100.0% 90,906 100.0% 
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To test the null hypothesis, we conducted a 
retrospective review of Italian national data from 
December 2015 to December 2018, collecting 
the number of patients starting DAA treatments 
due to an HCV infection before and after the 
expansion of the reimbursement criteria. Daily 
rates were calculated for patients starting DAAs 
according to each clinical criterion of reimburse-
ment defined by the NHS. The source of data 
was represented by the monitoring reports of 
DAA treatments of patients with HCV+ chronic 
hepatitis, published weekly on AIFA registries 
through their institutional website http://www.ai-
fa.gov.it5. The overall number of patients starting 
DAAs, was collected from each report published 
between 21 December 2015 to 24 December 2018, 
together with the distribution for each reimburse-
ment criterion.
Since we intended to retrospectively evaluate 
patient access to treatment after a public health 
decision on patient DAAs reimbursement criteria, 
the segmented regression of interrupted time se-
ries analysis was chosen as an appropriate design 
by which daily patient rate before and after im-
plementation of the decision could be compared, 
while taking into account also potential con-
founders6,7. The segmented regression analysis 
is the most commonly used approach to analyse 
interrupted time series data8. This regression re-
quires data collected regularly over time and or-
ganized at equally spaced intervals. However, in 
few cases, a linear interpolation was used to get 
the number of patients starting DAAs exactly for 
each week, along the entire three-year time series. 
The time series of the daily patient rate starting 
a DAAs is used to ascertain an underlying trend, 
which may be interrupted by the regulatory deci-
sion to enlarge the coverage of patient access to 
treatment, at a known time-point. With respect to 
the legally valid date (31 March 2017), actual pa-
tient access to DAA treatments according to new 
reimbursement criteria started one month later, 
from 1 May 2017. This last date was considered 
as reference of the point in time for all following 
analysis. The outcome of interest of the current 
study was the variable Yt that corresponds to the 
daily patient rate starting DAA treatments before 
and after the introduction of new reimbursement 
criteria. The time series of weekly number of 
patients starting DAA treatments was aggregated 
considering a time span of two-weeks. Thus, the 
daily patient rates were calculated at each time 
point as the number of patients starting DAA 
treatments per two-weeks.
Statistical Analysis
The regression model was specified to esti-
mate the level and trend in the daily patient rate 
starting DAAs before the introduction of new 
reimbursement criteria and the changes in lev-
el and trend following the introduction of new 
criteria. Details of the statistical analysis and 
regression model are available in the Supple-
mentary Method section. 
Results
Changes in the Features of the 
Patients Accessing Therapy According 
to Reimbursement Criteria
From the introduction of the first DAA in 2015 
to December 2018, overall 165,105 patients start-
ed a fully reimbursed DAA treatment in Italy, 
corresponding to a mean of about 41,276 patients 
per year. About half of them (i.e., 74,199) started 
the DAA treatment according to the initial reim-
bursement criteria (Table I). Access to DAAs was 
mostly for patients with cirrhosis, or for those 
having a hepatocellular carcinoma (i.e., first re-
imbursement criterion, 62.5% corresponding to 
46,338 out of 74,199), followed by patients having 
severe hepatic fibrosis (i.e., fourth reimbursement 
criterion, 28.3% corresponding to 20,974 out of 
74,199). 
After the expansion of reimbursement cri-
teria, between May 2017 and December 2018, 
90,906 patients started a DAA treatment (Ta-
ble I). The most frequent category of patients 
treated with DAAs became HCV patients with 
F0-F1 disease stage (i.e., eighth reimbursement 
criterion, 43.2% corresponding to 39,240 out 
of 90,906), followed by patients having a mild 
disease (F2, seventh reimbursement criterion, 
22.9% corresponding to 20,825 out of 90,906). 
Even if the reimbursement criterion for F2 pa-
tients (seventh) was included among initial reim-
bursement criteria, the actual access to DAAs 
for those patients started only after the introduc-
tion of new reimbursement criteria, after April 
2017 (Supplementary Figure 1). This is to be 
ascribed to the fact that the initial reimbursed 
treatment for those patients was the PegIFN + 
simeprevir combination only, which was indeed 
employed only in sporadic cases.
As a whole, after the expansion of reimburse-
ment criteria, there was an absolute reduction 
of 59.9% in the incidence of patients starting 
DAAs treatment according to initial criteria 
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(i.e., from the first to the sixth criterion). In the 
same period, there was an absolute increase 
of 66.0% in the incidence of patients starting 
DAAs treatment according to new reimburse-
ment criteria (i.e., from the seventh to the elev-
enth criterion).
Effect of Expansion of Reimbursement 
Criteria on the Rate of Treated Patients
Table II illustrates the results of the segment-
ed regression of interrupted time series analysis 
of daily patient rate starting DAA treatment in 
Italy, it shows the impact of expansion of reim-
bursement criteria on patient access. The model 
analysed the rate of overall patients starting 
DAA treatments at each time point, with all 
reimbursement criteria, the intercept β0 was 2.9 
patients per day, not statistically significant (p = 
0.713). As the baseline trend, the unstandardized 
β1 suggests a decreasing daily rate of patients 
of -0.431 per two-weeks, again not statistically 
significant (p = 0.256). The unstandardized β2 
was 22.9, indicating a significant level change 
in the rate immediately after the enlargement of 
reimbursement criteria (p = 0.023). The unstan-
dardized β3 was 0.125, indicating that there was 
an increasing trend albeit not statistically signif-
icant (p = 0.787) of the two-weeks rate after the 
expansion of reimbursement criteria compared 
with the previous trend. The proportion of ex-
plained variance by regression model was very 
low and not statistically significant (R square 
value was 0.08; p = 0.121). The Darbin-Watson’d 
value was 2.1. 
Although an overall increase of the daily 
patient rate immediately after the expansion of 
reimbursement criteria may be observed (Sup-
plementary Table I and Supplementary Fig-
ure 2), the data autocorrelation substantially 
biased the results (Darbin-Watson’d value was 
0.438 in Supplementary Table I), determining 
an overestimation of the statistical significance 
of the effects. After adjustment for the first-or-
der autocorrelation, the interruption of the time 
series by expansion of reimbursement criteria 
explained a very low variance proportion, not 
statistically significant (Figure 1). 
Reduction of the Treatment Rate  
of Patients With More Advanced 
Disease After Expansion of 
Reimbursement Criteria 
Table III shows the results of the segmented 
regression of interrupted time series analysis of 
daily patient rate starting DAA treatment accord-
ing to each initial criterion (in Supplementary 
Table II the same results on data not adjusted 
for first-order autocorrelation). The highest daily 
patient rate was registered among patients with 
cirrhosis and/or hepatocellular carcinoma [reim-
bursement criterion one; the intercept β0 being 
9.8 patients per day (p = 0.010)]. As the baseline 
trend, the unstandardized β1 suggests a decreas-
ing daily rate of patients of -0.382 per two-weeks, 
statistically significant (p = 0.033). The unstan-
dardized β2 was 2.7, indicating that there wasn’t 
a significant level change in the rate of patients 
Table II. Parameter estimates, standard errors and p-values from segmented regression models predicting daily patient rate 
starting DAA treatment, adjusted for first-order autocorrelation of data.
Overall patients
(R-square = 0.08; p = 0.121; Durbin-Watson’s d = 2.1) Coefficient SE t p-value
Intercept β0  2.916 7.890 0.370 0.713
Baseline trend β1 -0.431 0.377 -1.145 0.256
Level change after enlargement of reimbursement criteria β2 22.932 9.852 2.328 0.023
Trend change after enlargement of reimbursement criteria β3 0.125 0.461 0.272 0.787
Figure 1. Daily patient rate starting DAAs, before (circle 
indicators) and after extension of reimbursement criteria 
(black circle indicators). The graph shows daily rate of 
overall patients starting DAA treatments at each time point, 
with all reimbursement criteria.
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starting DAA treatments with first criterion, im-
mediately after the expansion of reimbursement 
criteria (p = 0.564). The unstandardized β3 was 
0.328, indicating that expansion of reimbursement 
criteria did not determine a significant increase in 
the rate of patients with cirrhosis and/or HCC 
treated with DAA (p = 0.131). The proportion of 
explained variance by regression model was low, 
but it was statistically significant (R square value 
was 0.11; p = 0.032). The Darbin-Watson’d value 
was 2.6. The described pattern is graphed in the 
Figure 2A.
With the exception of patients with advanced 
fibrosis (stage F3, reimbursement criterion 4, the 
intercept β0 was 3.5 patients per day, p = 0.108), 
mean values of less than one patient started DAA 
treatment with all remaining initial reimbursement 
criteria. Among these criteria, in patients starting a 
Table III. Parameter estimates, standard errors and p-values from segmented regression models predicting daily patient rate, 
adjusted for first-order autocorrelation of data, and performed for patient subgroups starting DAA treatment according to each 
reimbursement criteria. The criteria are ordered on the base of decreasing level of daily patient rate..
Criterion No. 1
(R-square = 0.11; p = 0.032; Durbin-Watson’s d = 2.6) Coefficient SE t p-value
Intercept β0  9.776 3.685 2.653 0.010
Baseline trend β1 -0.382 0.176 -2.173 0.033
Level change after enlargement of reimbursement criteria β2 2.663 4.601 0.579 0.564
Trend change after enlargement of reimbursement criteria β3 0.328 0.215 1.526 0.131
Criterion No. 4
(R-square = 0.11; p = 0.032; Durbin-Watson’s d = 2.4) Coefficient SE t p-value
Intercept β0  3.480 2.140 1.626 0.108
Baseline trend β1 -0.075 0.102 -0.734 0.465
Level change after enlargement of reimbursement criteria β2 -0.971 2.673 -0.363 0.717
Trend change after enlargement of reimbursement criteria β3 0.005 0.125 0.040 0.968
Criterion No. 3
(R-square = 0.10; p = 0.046; Durbin-Watson’s d = 2.5) Coefficient SE t p-value
Intercept β0  0.672 0.468 1.436 0.155
Baseline trend β1 -0.012 0.022 -0.521 0.604
Level change after enlargement of reimbursement criteria β2 -0.422 0.584 -0.722 0.473
Trend change after enlargement of reimbursement criteria β3 0.002 0.027 0.088 0.930
Criterion No. 2
(R-square = 0.08; p = 0.093; Durbin-Watson’s d = 2.3) Coefficient SE t p-value
Intercept β0  0.386 0.165 2.347 0.022
Baseline trend β1 -0.016 0.008 -2.021 0.047
Level change after enlargement of reimbursement criteria β2 0.083 0.206 0.403 0.688
Trend change after enlargement of reimbursement criteria β3 0.017 0.010 1.718 0.090
Criterion No. 5
(R-square = 0.23; p < 0.001; Durbin-Watson’s d = 2.8) Coefficient SE t p-value
Intercept β0  0.180 0.047 3.800 <0.001
Baseline trend β1 -0.007 0.002 -3.001 0.004
Level change after enlargement of reimbursement criteria β2 0.063 0.059 1.068 0.289
Trend change after enlargement of reimbursement criteria β3 0.005 0.003 1.654 0.102
Criterion No. 6
(R-square = 0.08; p = 0.094; Durbin-Watson’s d = 2.3) Coefficient SE t p-value
Intercept β0  -0.024 0.077 -0.316 0.753
Baseline trend β1 0.004 0.004 1.098 0.276
Level change after enlargement of reimbursement criteria β2 -0.078 0.097 -0.808 0.422
Trend change after enlargement of reimbursement criteria β3 -0.008 0.005 -1.697 0.094
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DAA treatment according to the fifth criterion (i.e., 
patient on the waiting-list for liver transplantation 
having MELD cirrhosis <25 and/or having HCC 
within the Milan criteria, with the possibility of 
being in the waiting-list for at least 2 months) a 
decreasing baseline trend of the daily rate along 
the time span was registered (the unstandardized 
β1 = -0.007 per two-weeks, p = 0.004). The pro-
portion of explained variance by regression model 
was 23% (R square value was 0.23; p < 0.001). 
The Darbin-Watson’d value was 2.8. The described 
pattern is depicted in Figure 2B.
As a whole, these findings suggest that, after 
the expansion of the reimbursement criteria, the 
baseline trend (β1) in daily patient recruitment rate 
decreased for almost all the initial reimbursement 
criteria, attaining however statistical significance 
only for the first and the fifth criteria. As a matter 
of fact, the incidence of the first criterion (i.e., reim-
bursement of DAAs in cirrhotic patients, or having 
a hepatocellular carcinoma) decreased from 62.5% 
of the overall patients starting a DAAs treatment 
up to April 2017, to 18.5% after the enlargement 
of the criteria until to December 2018 (Table I). To 
summarize, the decreasing baseline trend of daily 
patient rate according to initial reimbursement cri-
teria, involving patients having a more severe dis-
ease burden, has offset the patient access with new 
reimbursement criteria, involving patients having a 
less severe disease (e.g., with a METAVIR F0-F2).
Discussion
This study intended to produce a broad analy-
sis of the fluxes of patients accessing DAA thera-
py in Italy, showing that: (1) the expansion of the 
reimbursement criteria produced an increased ac-
cess to therapy by patients with low grade disease 
at the expenses of those with advanced disease; 
(2) the overall number of patients treated each 
week remained stable; (3) there was a decrease 
in the treatment rate of patients with advanced 
disease treated per week.
Availability of second generation DAA sig-
nificantly changed the clinical scenario for pa-
tients with HCV, transforming a chronic, diffi-
cult-to-treat and potentially lethal disease into 
a short-term treatable one. Since the very be-
ginning, a major concern was availability of 
medications to the general population, given the 
high costs of the new drugs and the disease prev-
alence. As a matter of fact, this issue was much 
more sensitive in countries with public, universal 
access to care, and a significant prevalence of 
HCV infected individuals, such as Italy. 
A plan for early access to therapy for patients 
with more advanced disease was put in place 
with the intention to combine DAA availability 
with affordability. This was followed in Italy at 
a later stage by universal extension of treatment. 
This approach was implemented with the utmost 
caution, in consideration of the fact that a precise 
epidemiological registry of patients affected by 
HCV did not exist, making any estimate on the 
potential number and the severity of patients 
rather loose. Studies that investigated disease 
prevalence provided only a broad, age-dependent 
estimated prevalence4. Moreover, since they had 
been conducted years earlier, they did not reflect 
the actual situation at the time of first negotiation. 
In Italy, full coverage of medication costs is 
granted on the basis of legislation in place and 
through criteria defined by the Italian Medi-
Figure 2. Daily patient rate starting DAAs, before (circle indicators) and after extension of reimbursement criteria (black 
circle indicators). The (A) graph shows daily rate of patients starting DAAs according to the first reimbursement criteria; (B) 
graph shows daily patient rate starting DAAs according to the fifth reimbursement criteria.
A B
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cines Agency (AIFA). Public funds provide full 
coverage of medication costs on the basis of 
specific reimbursement criteria. During 2015, in 
the case of HCV therapy, initial reimbursement 
criteria included patients at higher risk of disease 
progression or complications, such as patients 
with F3 disease stage or above (individuals who 
had cirrhosis, HCC, transplanted, transplanted in 
waiting lists and other more specific and severe 
conditions). As reported in Table I, more than 
70,000 patients falling into the original reim-
bursement criteria were treated in less than two 
years in one of probably largest public funded 
HCV treatment programs in the world. Follow up 
studies based on AIFA registries found that treat-
ment success in those patients was not different 
from what reported in pivotal studies9-14.
Reimbursement criteria were expanded during 
2017, granting access for DAAs therapy to all 
patients affected by HCV irrespectively of dis-
ease severity stage. Broadening the number of 
eligible patients on the basis of prevalence data 
led to hypothesize that medication uptake would 
ramp up after the elimination of restrictions for 
reimbursement. Notably, the current study shows 
that a completely different scenario occurred. As 
depicted in Figure 1, the treatment rate did not 
change after the extension of the reimbursement 
criteria. A minimal increase in the treatment rate 
occurred only during the first few weeks shortly 
after the extension, while the overall increase was 
not statistically significant. In order to confirm 
such evidence, the global number of patients 
treated within the same periods did not prove to 
be different (Table I). Clinical characteristics of 
the patients accessing to therapy showed clear 
changes. There was an increase in the number 
of patients with mild disease (F0-F2) in parallel 
with a decrease in the number of patients with 
advanced disease (Table I, Figure 2 and Supple-
mentary Figure 1). 
Those results can be explained in different 
ways. From an epidemiological point of view, 
it could be speculated that the total number of 
patients affected by HCV in Italy could be much 
less than what initially hypothesized. Since this 
can be considered a diseases with high preva-
lence but low incidence, which has spread out in 
this country mostly during the 50s-70s of the XX 
century,4, it could be postulated that the majority 
of infected people were not alive any longer at 
the time of the availability of DAAs. However, 
this hypothesis is in contrast with mortality 
data and, mostly, with recent data published by 
a patient advocacy group (EpaC Onlus, epac.it), 
which showed that patients who have an active 
medical costs exemption based on HCV infected 
status were more than 300,000. Patients with a 
certified diagnosis can be exempted and granted 
free access to diagnostic tests for the disease 
(i.e., no co-payment implied). Considering that 
the majority of people infected by HCV are 
unaware of their disease, this means that the 
current number of individuals residing in Italy 
and affected by HCV might be between 400,000 
and 600,000 individuals, depending on the mod-
elling used. 
Another explanation for the absence of a sig-
nificant increase in the HCV treatment rate after 
the approval of the new criteria is the absence in 
Italy of a national plan for case finding. Chron-
ic HCV infection is a subtle disease that goes 
asymptomatic for the majority of its natural his-
tory1-3, with a large proportion (up to 60%) of 
patients who remain undiagnosed15,16. Large scale 
testing and treatment are considered pillars of 
HCV elimination strategies1; therefore, the ab-
sence of screening/case finding programs limits 
the number of patients who could access therapy.
An additional factor which could explain the 
lack of treatment increase in Italy after the expan-
sion of access criteria is the fact that only select-
ed clinical centres with experience in hepatology 
can allow the prescription and reimbursement of 
DAAs. This was the approach taken at the time 
of first generation DAAs (boceprevir/telaprevir), 
given the complexity of that type of treatment. 
This was confirmed when marketing approval was 
granted for second generation DAAs since during 
the early access phases patients were more com-
plex because of advanced disease. Such cautionary 
measure which was logical and effective when 
enforced within its original scopes, became a lim-
iting factor for treatment uptakes when centres ca-
pacity, in a condition of less stringent criteria, was 
not adjusted to allow the increase in the number of 
patients managed in a given time frame. 
Expansion of access criteria reduced mostly 
the number of patients with advanced disease 
(Figure 2). This result could be explained by 
an operational selection by prescribing centres, 
which put less serious patients on hold waiting for 
the introduction of more efficient second genera-
tion DAAs, than those initially authorized. This 
determined a so called “warehouse effect”17, with 
the majority of the known patients with advanced 
disease treated immediately. The observed reduc-
tion in the treatment rate of severe patients before 
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the expansion of the access criteria (Figure 2) 
confirms this hypothesis. 
The Italian experience in the ongoing govern-
ment funded eradication program for HCV infec-
tion is certainly unique in terms of the prevalence 
of the disease, treated patients (almost 190,000 as 
of July 2019), and public expenditure of treatment 
costs. A recent study18 performed in Greece on a 
limited number of patient (500 individuals) hy-
pothesised that expansion of access to treatment 
to mild disease (F2) would increase the number 
of treated patients by 10%. Our study shows, 
by contrast, that in the absence of restrictions, 
between 22 and 43% will fall within the F2 and 
F0-F1 disease stages, respectively (Table I). 
Medications costs and disease stage-based re-
strictions to therapy are thought to be the major 
limiting factors to comply with WHO goals for 
HCV elimination by 2030 in European coun-
tries19-21. The present findings only partially con-
firm the WHO assumptions, showing instead that 
more determinant factors for HCV eradication 
are effective screening programs22 and capillar-
ization of drug prescription and availability. 
The results discussed here should be analysed 
within the international context of prices variability 
and reimbursement in several countries. The initial 
very high price of new DAAs constituted a barrier 
to patient access and is probably still delaying opti-
mal access to treatment especially in countries with 
high prevalence of HCV infection. A recent WHO 
analysis showed that DAAs prices are overall still 
unaffordable and unrelated to potential market size 
and/or GDP per capita23. This finding is confirmed 
in low and middle-income countries, even where 
the prices of DAAs are much lower than those 
paid in high-income24. As a consequence, many 
developed countries adopted restricting measures to 
DAAs prescription, limiting it to patients with most 
severe disease conditions19,21,24. 
An interesting example of international HCV 
eradication programs was run in Australia, where 
the DDAs have been available for all individuals 
with chronic HCV infections aged 18 years and 
older, regardless of disease stage, drug and alco-
hol use, and prescriber restrictions25. The national 
HCV treatment programme allows treatment to be 
prescribed not only by specialists (gastroenterolo-
gy and infectious diseases) but by all other medical 
practitioners. The scheme has specifically ensured 
access for prisoners and has no restrictions for 
treatment of HCV reinfection. A recent epide-
miological study26 conducted in the Australian 
healthcare context showed a relevant impact of this 
approach on hospitalization and mortality. Results 
show between 2015 and 2017 the declines of 21% 
and 17% in decompensated cirrhosis diagnoses and 
liver-related deaths, respectively. In the same three 
years’ period the expected 34% in HCC diagnoses 
and 19% increase in all-cause mortality without 
DAAs therapy introduction, were decreased to 8% 
and 3%, respectively. However, it is worth to note 
that in Australia, after an initial spread of patients 
treated with DAAs, 70,260 patients were enrolled 
over the period of March 2016 to December 2018, 
corresponding to about 24,777 patients per year27. 
This figure is substantially lower than what regis-
tered in Italy where, in a four-year period (i.e., De-
cember 2014 to December 2018) a mean of 41,276 
patients started a DAA every year.
In Germany, all patients with chronic HCV 
infection are eligible for treatment, regardless of 
their clinical stage, a provision similar to the one 
adopted in Italy after May 2017. However, after 
the introduction of new DAAs, only a moderate 
increase of monthly prescriptions of HCV treat-
ment, lower than what expected, was registered 
and is currently summing up to only 20,000 
patients per year. The authors speculated that the 
most probable causes of the difficulties in treating 
HCV infected individuals in Germany could be 
ascribed to the high prices of the DAAs28.
Prices of DAAs are high all over the world 
and poorly correlated with the actual payment 
capacity of the healthcare systems. In fact, there 
are cases, such as that of Australia, which adopt-
ed an unrestricted access model, but achieved an 
annual number of treated patients much lower 
and with a less impacting economic burden than 
countries like Italy.  
Overall, the lesson that we can learn from 
the patient access to DAAs is that in the case of 
high-priced medicines, even if in the presence of 
highly innovative products, the constrains of pub-
lic budget expenditure may tend to prevail over 
those of health protection. Even when this line 
of reasoning does not seem to hold, it is only be-
cause there is a low yearly uptake of patients for 
DAA treatments that, despite high prices, would 
be still affordable. The first price negotiations 
of DDAs for the NHS were very efficient with 
respect to other developed countries, due to also 
to the high prevalence of HCV infected people 
in Italy. As a consequence, Italy has shown the 
highest annual rate of patients treated with DAAs 
in the last four years.
Some limitations of the study should be con-
sidered. Firstly, the possibility that some Italian 
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patients having an early phase of HCV infection 
(Metavir score F0/F1), initially excluded by a re-
imbursed DAA treatment, have sought abroad the 
treatment. In particular, it was reported that some 
Italian citizens travelled in low income countries 
(such as India) to purchase medications to lower 
costs. Although there is no indication that this 
was a prevalent and a statistically significant 
phenomenon, the loss of traceability of these 
DAA treatments in the AIFA monitoring regis-
ters would have increased the total number of pa-
tients prior to March 2017. Another limitation of 
the study is that the relationship between patient 
rate and treatment outcomes in terms of sustained 
virologic response (SVR) was not analysed. In 
this regard, several observational studies9-14 based 
on real world evidence data have already found 
that the treatment outcomes in Italy did not differ 
from the outcomes published in pivotal study 
results. Furthermore, the inclusion of data, such 
as SVR within a real world monitoring registry 
many months after the conclusion of clinical 
monitoring, may be critical and in many cases in-
complete5, while the AIFA registries collect data 
on DAA treatments on a daily basis, with a cov-
erage of all Italian approved prescribing centres.
Conclusions
Our study showed that in spite of the fact that 
a no-limit reimbursement policy for DAAs pre-
scriptions to HCV infected individuals in Italy 
widened the types of patients who could have ac-
cess to innovative treatments, the process toward 
the eradication of HCV infection in Italy did not 
significantly change. The evidence provided in 
this study are useful to support future strategies 
in reaching goals set by the WHO to fight HCV 
infections in large communities. 
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